An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed.
A five-year study was carried out by a team led by Professor John Deanfield, from University College London (UCL), based on a trial - comprised of 17,604 adults over the age of 45 from 41 countries - from semaglutide manufacturer Novo Nordisk.
The study explored the anti-obesity drug sold under brand names Wegovy, Ozempic and Rybelsus and if it could reduce the risk of heart attacks or stroke in obese people without diabetes.
Ozempic is a drug typically used to treat diabetes but recently gained a reputation among TikTok influencers and celebrities for helping them lose weight in short time frames.
@uktoday_ What is the Ozempic and why is it being used as a weight loss drug? #uknews #ozempicweightloss #diabetes #uknewsheadlines ♬ original sound - UKToday 🇬🇧 Newsquest
It contains semalgitude, which lowers blood sugar levels and regulates insulin, crucial for people with Type 2 diabetes.
However, it also mimics a hormone which limits are appetite by signalling to our bodies that we feel full.
As a result, people with obesity have lost weight while taking it, and it has even been used in a weight loss drug approved for use by the NHS in England.
Additional health benefits of anti-obesity drug Ozempic
Now, on top of helping with weight loss and diabetes, the drug is said to help reduce the risk of heart attacks, strokes and heart failure.
Prof Deanfield’s analysis of the trial examined the amount of time before patients suffered major cardiovascular events – such as heart attack or stroke – or whether they developed heart failure.
The research found semaglutide found in the drug reduced the risk of a heart attack and/or stroke in obese people with cardiovascular disease by a fifth.
A 2.4mg once-weekly dose of Wegovy, alongside standard care for the prevention of heart attacks or stroke, lowered the risk by 20% compared with those given a placebo.
The study aslo showed that after 20 weeks of being on semaglutide, 62% of patients had lost more than 5% of their bodyweight compared with 10% in the placebo group.
But the risk reduction of heart attacks, stroke or heart failure was similar in all patients regardless of how much weight they lost, or even if they gained weight.
Prof Deanfield said the findings “have important clinical implications”.
“Around half of the patients that I see in my cardiovascular practice have levels of weight equivalent to those in the Select trial and are likely to derive benefit from taking semaglutide on top of their usual level of guideline-directed care,” he added.
“Our findings show that the magnitude of this treatment effect with semaglutide is independent of the amount of weight lost, suggesting that the drug has other actions which lower cardiovascular risk beyond reducing unhealthy body fat.
“These alternative mechanisms may include positive impacts on blood sugar, blood pressure or inflammation, as well as direct effects on the heart muscle and blood vessels, or a combination of one or more of these.”
Dr Amir Khan says additional health benefits of anti-obesity drug is "positive news"
Dr Amir Khan appeared on Good Morning Britain (GMB) on Tuesday (May 14) speaking to Susanna Reid and Ed Balls about the findings from the study.
He said it was "positive news in our fight against cardiovascular disease".
Medics are calling for millions of people to be prescribed weight loss injections - known as Ozempic and Wegovy - after research found that they slashed the chances of heart attacks, strokes and even some cancer. @DrAmirKhanGP explains the findings of the research. pic.twitter.com/LUW7jia7qI
— Good Morning Britain (@GMB) May 14, 2024
Dr Khan said: "Those that were given the drug had a 20% recued risk of a heart attack, stroke or cardiovascular disease, that's regardless of how much weight they lost.
"That goes to show that this drug does more than just cause weight loss and manage blood sugars sugar, it could reduce inflammation, it could reduce blood pressure - those are the mechanisms of action by which we think it reduces those diseases we've listed there."
But he added that things like the anti-obesity jabs weren't the only way to deal with health problems.
Dr Khan said: "But what I will say Ed, and this is what I say to all my patients, if we do want to reduce the risk of cardiovascular disease, or any disease in all of us really, we should all be doing things like better nutrition focused on core foods; good, enjoyable, regular movement; good quality sleep; time in nature; and of course stopping smoking and reducing our alcohol intake, that is better than any drug I think."
RECOMMENDED READING:
- GMB presenter Susanna Reid reveals health scare that saw her miss several shows
- Dr Michael Mosley has his say on alcohol and it's good news for wine lovers
Since it was revealed Ozempic helped with weight loss the drug has been a lot harder for people to get a hold of, Dr Khan said.
"What I will say, and this is really important, since it's been licenced for weight loss it's been really really difficult for people with type two diabetes to get a hold of it," he said.
"A lot of my patients struggle to get hold of it and that has resulted in poorer blood sugar control for them, so we need to focus on the people who need it most."
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel